Progyny 3rd Quarter 2026 Earnings Conference Call - PROGYNY INC

Explicit Guidance:

• Full Year 2026: Revenue guidance raised to $1.365–$1.385 billion (5.9%–7.5% growth; 10.1%–11.7% excluding $48.5M from a former client). Adjusted EBITDA projected at $235–$240 million; Net Income at $107–$110.6 million. Adjusted EPS expected at $2.09–$2.13 on ~82 million fully diluted shares.
• Fourth Quarter 2026: Revenue projected at $344.7–$364.6 million (8.3%–14.6% growth). Adjusted EBITDA expected between $57.9–$62.9 million; Net Income between $28.5–$32.1 million. Adjusted EPS projected at $0.53–$0.58 on ~79 million fully diluted shares.
• Share Count: Utilized ~79–82 million fully diluted shares for Q4 and FY26 EPS calculations; net share count reduced by nearly 15% over the past year via buybacks.

Business-Segment Outlook:

• Client & Life Growth: Entering 2027 with an anticipated book of >660 clients and 8.3 million covered lives. 1.3 million new lives added in the recent selling season (100k incremental since last update) are expected to launch primarily in Q1 2027, with several hundred thousand launching mid-year.
• Retention & Expansion: Achieved near 100% retention of the existing base; approximately 20% of the base committed to expand solutions (consolidating services) for 2027.
• Product Attach: Near 100% attach rate for Progeny Rx in new business (2026 cohort); expects 95%–96% overall RX attachment by 2027. Over 3 million lives expected to utilize expanded products beyond RX starting in 2027.
• Progeny Select: Fully insured market offering (Progeny Select) remains immaterial to current results; focus is on infrastructure building to scale as a long-term growth driver.
• Utilization Trends: Utilization for the new 1.3 million life cohort expected to be slightly lower than the average book due to underwriting specifics, particularly for the largest public sector client (CalPERS). Overall utilization for 2027 to be assessed based on early-year performance during the Feb 2027 guidance update.

Market and Competitive Outlook:

• Competitive Landscape: Market rationalization observed with competitors exiting or downsizing; Progeny capturing share from rivals (including takeaways from the largest employer's previous provider). Differentiation driven by cost containment, outcomes, and member experience in an inflationary environment.
• Demand Drivers: Sustained high demand fueled by medical cost inflation, 1-in-5 infertility prevalence (CDC data), and employer focus on millennial workforce retention.
• Geographic/Industry Mix: Wins represent a diverse cross-section of the economy (universities, tech leaders, banks, public health funds) with client sizes ranging from 1,000 to >100,000 lives; no single geography or client makes an outsized contribution.
• Partnerships: Cigna (national partner) and largest regional plans driving channel growth; "brownfield" and "greenfield" wins remain balanced (slightly more brownfield).

Macro / Industry Outlook:

• Medical Inflation: Acknowledges continued high medical cost inflation and GLP-1 drug costs driving employer demand for specialized fertility benefits to control trends.
• Economic Environment: Market momentum reflects a "well-functioning market" where capital flows to proven models; demand for this critical benefit is viewed as resilient regardless of broader economic mix.
• Utilization Patterns: Seasonal engagement reverts to normal ranges post-summer; Q4 (Oct/Nov) historically strong.

Strategic Initiatives:

• Investment Tapering: Expectation to taper back investment cycles throughout 2027 as growth stabilizes and integrations complete, potentially allowing incremental gross profit to flow through to EBITDA.
• Platform Expansion: Continued investment in care management delivery efficiencies and solution platform enhancements; CapEx remains modest at ~2% of revenue (approx. $9M YTD).
• Data & Systems: Goal to have eligibility files for >50% of lives by year-end; focus on integrating client data systems to support operations.
• M&A/Integrations: Ongoing integration of acquired companies and platform consolidation expected to conclude, contributing to margin recovery.

Risks and Headwinds to Outlook:

• Timing of Launches: Variability in the timing of new client go-lives (Q1 vs. mid-year) could impact short-term revenue recognition and utilization metrics.
• Utilization Variance: Actual utilization and ART cycle intensity in 2027 may differ from expectations; specific guidance for 2027 will be set after observing early-year utilization trends.
• Stock Compensation: Future margins may fluctuate based on the remaining expense from past stock grants rolling off in 2026.
• External Factors: Potential changes in medical cost inflation, regulatory shifts, or unexpected client behavior could alter growth trajectories or margin expansion expectations.

Management Tone on the Future:

• Confidence Level: High confidence; described as "exceptionally well positioned" with the "strongest sales momentum ever."
• Guidance Stance: Upward revision of full-year 2026 midpoints based on strong execution and healthy engagement.
• Caveats: Management explicitly states they will not hang "hat on any one opportunity" and maintains a disciplined approach to guidance, reserving detailed 2027 visibility for the February call after observing early utilization.
• Strategic Outlook: Viewed as a transition from heavy investment to a phase of margin expansion and capital return (share buybacks continue with ~$51M remaining under authorization).

Miscellaneous:

• Capital Allocation: $56M operating cash flow generated in Q3; trailing 12-month OCF at $207M. Net debt is zero; no use planned for the $200M revolving credit facility.
• Buyback Activity: Purchased 5.5 million shares cumulatively since May under current $200M authorization; ~14 million shares repurchased since November overall.